Displacement cloud maps. by Maogang Tian (21485116)

Subjects:

Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

“…<b>(B)</b> A significant decrease in the proliferative clonal capacity of U251MG colonies was observed with 50ΜM and 100ΜM SHG-44 treatment. …”

Herbicide doses corresponding to 20 and 50% plant growth reduction of canola, chickpea, and wheat. by Win Win Pyone (20396432)

HDECO: A method for Decreasing energy and cost by using virtual machine migration by considering hybrid parameters by Arash GhorbanniaDelavar (22563696)

“…<h2>Summary</h2><p dir="ltr">This research introduces <b>HDECO</b> (Hybrid Decreasing Energy and Cost Optimization) — a method designed to reduce both energy consumption and execution cost in cloud datacenters through intelligent virtual machine migration. …”

Point cloud fusion instance effect. by Hongliang Zou (20707270)

Subjects:

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

Metformin lotion decreases collagen III levels in the wounded skin of rats after 10 days of wound healing. by Jianying Zhang (256508)

Subjects:

Metformin lotion decreases collagen III levels in the wounded skin of rats after 10 days of wound healing. by Jianying Zhang (256508)

Subjects:

Metformin lotion decreases TGF-β1 levels in the wounded skin of rats after 10 days of wound healing. by Jianying Zhang (256508)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline T-cell exhaustion, monocyte activation and platelet activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline T-cell activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Subjects:

Thematic clouds for lectures. by Ignacio García-Espona (21395335)